Pricing Log in Create free account
Friday 6 November 2026 Export GRAL’s income statement to Excel — free account

GRAIL, Inc.

GRAL Healthcare Diagnostics & Research

GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.

Revenue
+3.71%
EPS
+10.2%
Free cash flow
−24.9%

Quarter to September 2026, against a year earlier

124.40 19.26 −13.41%
Market cap
$5.3B
P/E
0.0×
Fwd P/E
−14.5×
Dividend yield
—
F-score
6/9
Altman Z
0.37
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

GRAIL, Inc. (GRAL) Current ratio

Alert me on Current ratio

GRAIL, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 8.9×, down 3.0× from fiscal 2025 (12.0×). That is above the Diagnostics & Research industry median of 2.3× and above the Healthcare sector median of 3.1×.

Current ratio, annual

Embed this chart

Annual newest first

Period Current ratio Change
FY2025 12.0× 12.33%
FY2024 10.7× 1,017.30%
FY2023 1.0× —

Quarterly newest first

Period Current ratio Change
Sep 2026 8.9× (18.40%)
Jun 2026 10.9× (6.76%)
Mar 2026 11.7× (1.91%)
Dec 2025 12.0× 57.29%
7 more quarters

Current ratio against peers

Company Current ratio
BLLN BillionToOne, Inc. compare 11.2×
GRAL GRAIL, Inc. 8.9×
VCYT Veracyte, Inc. compare 5.6×
ADPT Adaptive Biotechnologies Corporation compare 4.0×
SHC Sotera Health Company compare 3.1×
QGEN QIAGEN N.V. compare 2.8×
CDNA CareDx, Inc. compare 2.3×
RDNT RadNet, Inc. compare 1.5×
ICLR ICON PLC compare 1.3×
Diagnostics & Research industry median 2.3×
Healthcare sector median 3.1×
Market median 1.6×

What Current ratio is

Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.

Current Assets (Total) ÷ Current Liabilities (Total)

The full definition of Current ratio →

More on GRAL